The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Here's what doctors want you to know about Spravato, plus potential side effects to be aware of. Thea Gallagher, PsyD, is a clinical associate professor at NYU Langone Health and cohost of the ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

But it remains costly — and controversial Health Canada approved a prescription esketamine nasal spray called Spravato in ...

These side effects and the potential risk of harmful dependence have led to the FDA mandating a special treatment strategy for providing Spravato to patients, known as a Risk Evaluation and ...

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

Spravato’s warning label cautions about the risk of sedation and dissociation, respiratory depression, suicidal thoughts, and abuse or misuse of the drug, among other potential side effects.